Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting

Journal of ECT

Volumn 28, Issue 3, 2012, Pages 157-161

  Abdallah, Chadi G ^a   Fasula, Madonna ^a   Kelmendi, Ben ^a   Sanacora, Gerard ^a   Ostroff, Robert ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antidepressant; barbiturate; ECT; ketamine; rapid

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; BENZATROPINE; CITALOPRAM; CLONAZEPAM; DULOXETINE; FLUOXETINE; KETAMINE; LAMOTRIGINE; LEVOTHYROXINE SODIUM; LIOTHYRONINE; LITHIUM; LORAZEPAM; METHYLPHENIDATE; PAROXETINE; QUETIAPINE; RISPERIDONE; THIOPENTAL; TRAZODONE; VALPROIC ACID; VENLAFAXINE;

ADULT; AGED; ANESTHESIA; ANTIDEPRESSANT ACTIVITY; ARTICLE; BECK DEPRESSION INVENTORY; BIPOLAR DISORDER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PILOT STUDY; POST HOC ANALYSIS;

ADOLESCENT; ADULT; AGED; ANESTHESIA; ANESTHETICS, DISSOCIATIVE; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; COMBINED MODALITY THERAPY; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; KETAMINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEIZURES; THIOPENTAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865777512     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0b013e31824f8296     Document Type: Article

References (41)

1. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351-354.
2. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793-802.
3. Valentine GW, Mason GF, Gomez R, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 2011;191:122-127.
4. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-864.
5. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139-145.
6. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71:1605-1611.
7. Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1155-1159.
8. Machado-Vieira R, Yuan P, Brutsche N, et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry. 2009;70:1662-1666.
9. Mathew SJ, Murrough JW, aan het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13:71-82.
10. Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry. 2009;65:181-184.
11. Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66:522-526.
12. Salvadore G, Cornwell BR, Colon-Rosario V, et al. Increased anterior cingulate cortical activity in response to fearful faces: A neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry. 2009;65:289-295.
13. Salvadore G, Cornwell BR, Sambataro F, et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology. 2010;35:1415-1422.
14. Katz MM, Tekell JL, Bowden CL, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004;29:566-579.
15. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STA.R. *D: Implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
16. American Psychiatric Association Committee on Electroconvulsive Therapy, Weiner RD. The Practice of Electroconvulsive Therapy: RECOMMENDATIONS for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association. 2nd ed. Arlington, VA: AMERICAN Psychiatric Publishing, Inc; 2001.
17. Nobler MS, Sackeim HA, Moeller JR, et al. Quantifying the speed of symptomatic improvement with electroconvulsive therapy: Comparison of alternative statistical methods. Convuls Ther. 1997;13:208-221.
18. Green CD. Ketamine as an anaesthetic for ECT. Br J Psychiatry. 1973;122:123-124.
19. Brewer CL, Davidson JR, Hereward S. Ketamine (''Ketalar''): A safer anaesthetic for ECT. Br J Psychiatry. 1972;120:679-680.
20. Krystal AD, Weiner RD, Dean MD, et al. Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. J Neuropsychiatry Clin Neurosci. 2003;15:27-34.
21. McDaniel WW, Sahota AK, Vyas BV, et al. Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies. J ECT. 2006;22:103-106.
22. Okamoto N, Nakai T, Sakamoto K, et al. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: Comparing ketamine and propofol anesthesia. J ECT. 2010;26:223-227.
23. Kranaster L, Kammerer-Ciernioch J, Hoyer C, et al. Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: A retrospective study. Eur Arch Psychiatry Clin Neurosci. 2011;261(8):575-582.
24. Duncan GE, Moy SS, Knapp DJ, et al. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: Potential relevance to schizophrenia. Brain Res. 1998;787:181-190.
25. Moghaddam B, Adams B, Verma A, et al. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921-2927.
26. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959-964.
27. First M, Spitzer R, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders: PATIENT Edition (SCIDI/P. Version 2.0). New York, NY: BIOMETRIC Research, New York State Psychiatric Institute; 1995.
28. Hamilton M. Standardised assessment and recording of depressive symptoms. Psychiatr Neurol Neurochir. 1969;72:201-205.
29. Beck Robert A, Aaron T. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev. 1988;8:77-100.
30. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14:1127-1131.
31. Kudoh A, Takahira Y, Katagai H, et al. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002;95:114-118.
32. Goforth HW, Holsinger T. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J ECT. 2007;23:23-25.
33. Ho IK, Harris RA. Mechanism of action of barbiturates. Annu Rev Pharmacol Toxicol. 1981;21:83-111.
34. Kamiya Y, Andoh T, Furuya R, et al. Comparison of the effects of convulsant and depressant barbiturate stereoisomers on AMPA-type glutamate receptors. Anesthesiology. 1999;90:1704-1713.
35. Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res. 2011;224:107-111.
36. Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349-352.
37. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007;27:11496-11500.
38. Loo C, Simpson B, MacPherson R. Augmentation strategies in electroconvulsive therapy. J ECT. 2010;26:202-207.
39. Loo CK, Kaill A, Paton P, et al. The difficult-to-treat electroconvulsive therapy patientVstrategies for augmenting outcomes. J Affect Disord. 2010;124:219-227.
40. Lunn RJ, Savageau MM, Beatty WW, et al. Anesthetics and electroconvulsive therapy seizure duration: Implications for therapy from a rat model. Biol Psychiatry. 1981;16:1163-1175.
41. Rasmussen KG, Jarvis MR, Zorumski CF. Ketamine anesthesia in electroconvulsive therapy. Convuls Ther. 1996;12:217-223.